Effects of 500 mcg roflumilast on inflammatory cells and mediators in BAL fluid after segmental pulmonary LPS challenge in healthy volunteers – ERIC

Study identifier:BY217/M2-117

ClinicalTrials.gov identifier:N/A

EudraCT identifier:

CTIS identifier:N/A

Study Complete

Official Title

*Please Note* The Study you are attempting to view was acquired from Takeda by AstraZeneca and was disclosed initially by Takeda per their Transparency Policies. More information regarding this study may be available by contacting [email protected].

Medical condition

Chronic Obstructive Pulmonary Disease

Phase

Phase 1

Healthy volunteers

Yes

Study drug

Sex

All

Actual Enrollment

Study type

Interventional

Age

18 Years - 45 Years

Date

Study Start Date: 01 Jul 2004

Primary Completion Date: -

Study Completion Date: 01 Mar 2005

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jun 2016 by Takeda

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

Documents available

BY217-M2-117-RDS-2014-10-26.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information Center

1-877-240-9479

[email protected]